Besides, the experimental validation results also unraveled that ZFP36L1 expression exhibited significant down-regulation in AML patients compared with the normal controls both at the mRNA (Fig. 2b) and protein (Fig. 2c) levels, and also remarkable time-course up-regulation during PMA-induced moncytic differentiation of THP-1 cells (Fig. 2d) and HL-60 cells (Fig. 2e) as well as in vitro monocytic induction culture of CD34+ HSPCs (Fig. 2f), all in accordance with array data analyzed before. The gene discussed is ZFP36L1; the disease is acute myeloid leukemia.